Jiang YJ, Wu L, Yang X, Pu Y, Ning BJ, Peng N, Zhu XJ. Dermatitis bullosa caused by the immune checkpoint inhibitor camrelizumab: A case report. World J Clin Cases 2025; 13(8): 97677 [DOI: 10.12998/wjcc.v13.i8.97677]
Corresponding Author of This Article
Xiao-Ju Zhu, MSc, RN, Chief Nurse, Cancer Center, Daping Hospital, Army Medical University, No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China. 277264923@qq.com
Research Domain of This Article
Dermatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Mar 16, 2025; 13(8): 97677 Published online Mar 16, 2025. doi: 10.12998/wjcc.v13.i8.97677
Dermatitis bullosa caused by the immune checkpoint inhibitor camrelizumab: A case report
Yuan-Jing Jiang, Lu Wu, Xiao Yang, Yu Pu, Bing-Jie Ning, Na Peng, Xiao-Ju Zhu
Yuan-Jing Jiang, Lu Wu, Xiao Yang, Yu Pu, Bing-Jie Ning, Na Peng, Xiao-Ju Zhu, Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China
Co-first authors: Yuan-Jing Jiang and Lu Wu
Author contributions: Jiang YJ, the patient’s supervising nurse, conducted the study, performed the literature review, contributed to manuscript preparation, and oversaw critical revisions for intellectual accuracy; Wu L, Yang X, Pu Y, Ning BJ, Peng N and Zhu XJ assisted in the literature review and contributed to the drafting of the manuscript; All authors provided final approval for the submitted version.
Informed consent statement: Written informed consent was obtained for the immunotherapy.
Conflict-of-interest statement: All authors have completed the ICMJE uniform disclosure form and report no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Ju Zhu, MSc, RN, Chief Nurse, Cancer Center, Daping Hospital, Army Medical University, No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China. 277264923@qq.com
Received: June 5, 2024 Revised: October 9, 2024 Accepted: November 25, 2024 Published online: March 16, 2025 Processing time: 182 Days and 3.3 Hours
Core Tip
Core Tip: The use of immune checkpoint inhibitors has complemented and enriched the treatment options other than radiation and chemotherapy, and has been recognized by the tumor population. The growing availability and clinical use of immune checkpoint inhibitors have raised significant clinical concerns regarding their safety. Timely identification and diagnosis, coupled with multidisciplinary consultation and the prompt administration of immunosuppressants, can effectively address severe immune-related adverse reactions. This report outlines the treatment course and outcome of a case featuring immune-related cutaneous adverse reactions, hope to provide different perspectives for immunotherapy and care of tumors to get the attention of peers and promote the development of related technologies.
